Deal Details
Geron Completes $227.8 Million Follow-On Offering
Summary
Geron Corporation (“Geron”) (NASDAQ: GERN) recently completed an upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters’ option to purchase additional shares of common stock for total gross proceeds of $227.8 million. Geron intends to use the proceeds from this offering to fund preparatory activities for the potential U.S. commercial launch of imetelstat.
The offering consisted of 68,007,741 shares of common stock at an offering price of $2.45 per share, which includes 12,131,444 shares of common stock pursuant to the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 25,000,000 shares of common stock at an offering price of $2.449 per pre-funded warrant.
Baird acted as a co-lead manager on this offering.
About
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Geron investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. Geron Corporation is headquartered in Foster City, California.CONTACT US TO LEARN MORE
- Date
- January 2023
- Company
- Geron Corporation
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
